Call it venture philanthropy with a twist: If all goes as planned, the Juvenile Diabetes Research Foundation will co-own a series of companies dedicated to type 1 diabetes treatments without violating tax code, thanks to a structure created by Boston’s PureTech Ventures.

Call it venture philanthropy with a twist: if all goes to plan, the Juvenile Diabetes Research Foundation will co-own a series of biotech companies dedicated to type 1 diabetes treatments without violating tax code, thanks to a structure created by Boston’s PureTech Ventures.

Call it venture philanthropy with a twist: if all goes to plan, the Juvenile Diabetes Research Foundation will co-own a series of biotech companies dedicated to type 1 diabetes treatments without violating tax code, thanks to a structure created by Boston’s PureTech Ventures.

Our survey of news and notes from the second day of the BIO conference includes discussions of changes in the way pharma negotiates milestones, big ambitious projects to solve industry “dysfunction,” and a next-generation antibody developer pushing toward the clinic.